Christopher Norbert Johnson
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Christopher Norbert Johnson has a total of 179 co-authors. Here are the top co-authors by number of shared publications:
- Gianni Chessari
Astex Pharmaceuticals, 436 Cambridge Science Park, Cambridge CB4 0QA, U.K.
7 shared publications - Wolfgang Jahnke
Novartis Biomedical Research, Basel, Switzerland
7 shared publications David C. Rees
6 shared publications- Iwan J. P. de Esch
Faculty of Science, Department of Chemistry and Pharmaceutical Sciences, Division of Medicinal Chemistry, Amsterdam Institute for Molecular and Life Sciences (AIMMS), Vrije Universiteit Amsterdam
6 shared publications - Paul Neil Mortenson
Astex Pharmaceuticals, 436 Cambridge Science Park, Milton Road, Cambridge CB4 0QA, U.K.
6 shared publications - Daniel Andrew Erlanson
Frontier Medicines, 151 Oyster Point Blvd., South San Francisco, California 94080, United States
5 shared publications
Latest Publications
- 13 January 2026
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 69 (3) , 3639-3640
Correction to “Fragment-to-Lead Medicinal Chemistry Publications in 2024: A Tenth Annual Perspective”
- 13 January 2026
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 69 (3) , 3639-3640
Correction to “Fragment-to-Lead Medicinal Chemistry Publications in 2024: A Tenth Annual Perspective”
- 25 November 2025
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 68 (23) , 24830-24847
Fragment-to-Lead Medicinal Chemistry Publications in 2024: A Tenth Annual Perspective
Fragment-based drug discovery (FBDD) has led to dozens of clinical compounds, including eight approved drugs. For the past decade, we have published an annual review of successful fragment-to-lead (F2L) medicinal chemistry programs. This Perspective marks the tenth in the series. We analyze the 18 F2L case studies from 2024 and put them in the context of the larger set of 233 examples dating back to 2015. We hope that the lessons herein will both inform and inspire researchers to discover the next generation of drugs.
- 25 November 2025
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 68 (23) , 24830-24847
Fragment-to-Lead Medicinal Chemistry Publications in 2024: A Tenth Annual Perspective
Fragment-based drug discovery (FBDD) has led to dozens of clinical compounds, including eight approved drugs. For the past decade, we have published an annual review of successful fragment-to-lead (F2L) medicinal chemistry programs. This Perspective marks the tenth in the series. We analyze the 18 F2L case studies from 2024 and put them in the context of the larger set of 233 examples dating back to 2015. We hope that the lessons herein will both inform and inspire researchers to discover the next generation of drugs.
- Open Access
High throughput cryo-EM provides structural understanding for modulators of the lysosomal ion channel TRPML1
- 8 May 2025
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 68 (10) , 10497
Correction to “Fragment-Based Discovery of Allosteric Inhibitors of SH2 Domain-Containing Protein Tyrosine Phosphatase-2 (SHP2)”
- 8 May 2025
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 68 (10) , 10497
Correction to “Fragment-Based Discovery of Allosteric Inhibitors of SH2 Domain-Containing Protein Tyrosine Phosphatase-2 (SHP2)”
- 27 June 2024
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 67 (13) , 11168-11181
Fragment-Based Discovery of a Series of Allosteric-Binding Site Modulators of β-Glucocerebrosidase
Beta-Glucocerebrosidase (GBA/GCase) mutations leading to misfolded protein cause Gaucher's disease and are a major genetic risk factor for Parkinson's disease and dementia with Lewy bodies. The identification of small molecule pharmacological chaperones that can stabilize the misfolded protein and increase delivery of degradation-prone mutant GCase to the lysosome is a strategy under active investigation. Here, we describe the first use of fragment-based drug discovery (FBDD) to identify pharmacological chaperones of GCase. The fragment hits were identified by using X-ray crystallography and biophysical techniques. This work led to the discovery of a series of compounds that bind GCase with nM potency and positively modulate GCase activity in cells.
- 27 June 2024
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 67 (13) , 11168-11181
Fragment-Based Discovery of a Series of Allosteric-Binding Site Modulators of β-Glucocerebrosidase
Beta-Glucocerebrosidase (GBA/GCase) mutations leading to misfolded protein cause Gaucher's disease and are a major genetic risk factor for Parkinson's disease and dementia with Lewy bodies. The identification of small molecule pharmacological chaperones that can stabilize the misfolded protein and increase delivery of degradation-prone mutant GCase to the lysosome is a strategy under active investigation. Here, we describe the first use of fragment-based drug discovery (FBDD) to identify pharmacological chaperones of GCase. The fragment hits were identified by using X-ray crystallography and biophysical techniques. This work led to the discovery of a series of compounds that bind GCase with nM potency and positively modulate GCase activity in cells.
- 11 March 2024
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 67 (6) , 4655-4675
Fragment-Based Discovery of Allosteric Inhibitors of SH2 Domain-Containing Protein Tyrosine Phosphatase-2 (SHP2)
The ubiquitously expressed protein tyrosine phosphatase SHP2 is required for signaling downstream of receptor tyrosine kinases (RTKs) and plays a role in regulating many cellular processes. Genetic knockdown and pharmacological inhibition of SHP2 suppresses RAS/MAPK signaling and inhibit the proliferation of RTK-driven cancer cell lines. Here, we describe the first reported fragment-to-lead campaign against SHP2, where X-ray crystallography and biophysical techniques were used to identify fragments binding to multiple sites on SHP2. Structure-guided optimization, including several computational methods, led to the discovery of two structurally distinct series of SHP2 inhibitors binding to the previously reported allosteric tunnel binding site (Tunnel Site). One of these series was advanced to a low-nanomolar lead that inhibited tumor growth when dosed orally to mice bearing HCC827 xenografts. Furthermore, a third series of SHP2 inhibitors was discovered binding to a previously unreported site, lying at the interface of the C-terminal SH2 and catalytic domains.
- 11 March 2024
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 67 (6) , 4655-4675
Fragment-Based Discovery of Allosteric Inhibitors of SH2 Domain-Containing Protein Tyrosine Phosphatase-2 (SHP2)
The ubiquitously expressed protein tyrosine phosphatase SHP2 is required for signaling downstream of receptor tyrosine kinases (RTKs) and plays a role in regulating many cellular processes. Genetic knockdown and pharmacological inhibition of SHP2 suppresses RAS/MAPK signaling and inhibit the proliferation of RTK-driven cancer cell lines. Here, we describe the first reported fragment-to-lead campaign against SHP2, where X-ray crystallography and biophysical techniques were used to identify fragments binding to multiple sites on SHP2. Structure-guided optimization, including several computational methods, led to the discovery of two structurally distinct series of SHP2 inhibitors binding to the previously reported allosteric tunnel binding site (Tunnel Site). One of these series was advanced to a low-nanomolar lead that inhibited tumor growth when dosed orally to mice bearing HCC827 xenografts. Furthermore, a third series of SHP2 inhibitors was discovered binding to a previously unreported site, lying at the interface of the C-terminal SH2 and catalytic domains.
- 24 November 2023
- Published by Royal Society of Chemistry (RSC) in RSC Medicinal Chemistry
- Vol. 14 (12) , 2699-2713
Enabling synthesis in fragment-based drug discovery (FBDD): microscale high-throughput optimisation of the medicinal chemist's toolbox reactions
Democratised high-throughput experimentation for FBDD.
- 24 November 2023
- Published by Royal Society of Chemistry (RSC) in RSC Medicinal Chemistry
- Vol. 14 (12) , 2699-2713
Enabling synthesis in fragment-based drug discovery (FBDD): microscale high-throughput optimisation of the medicinal chemist's toolbox reactions
Democratised high-throughput experimentation for FBDD.
- Top Cited PapersOpen Access
- 13 April 2023
- Published by American Chemical Society (ACS) in ACS Central Science
- Vol. 9 (5) , 957-968
Accelerated Chemical Reaction Optimization Using Multi-Task Learning
- 13 April 2023
- Published by American Chemical Society (ACS) in ACS Central Science
- Vol. 9 (5) , 957-968
Top Cited PapersOpen AccessAccelerated Chemical Reaction Optimization Using Multi-Task Learning
- Top Cited PapersOpen Access
- 23 February 2023
- Published by American Chemical Society (ACS) in Chemical Reviews
- Vol. 123 (6) , 3089-3126
A Brief Introduction to Chemical Reaction Optimization
From the start of a synthetic chemist's training, experiments are conducted based on recipes from textbooks and manuscripts that achieve clean reaction outcomes, allowing the scientist to develop practical skills and some chemical intuition. This procedure is often kept long into a researcher's career, as new recipes are developed based on similar reaction protocols, and intuition-guided deviations are conducted through learning from failed experiments. However, when attempting to understand chemical systems of interest, it has been shown that model-based, algorithm-based, and miniaturized high-throughput techniques outperform human chemical intuition and achieve reaction optimization in a much more time- and material-efficient manner; this is covered in detail in this paper. As many synthetic chemists are not exposed to these techniques in undergraduate teaching, this leads to a disproportionate number of scientists that wish to optimize their reactions but are unable to use these methodologies or are simply unaware of their existence. This review highlights the basics, and the cutting-edge, of modern chemical reaction optimization as well as its relation to process scale-up and can thereby serve as a reference for inspired scientists for each of these techniques, detailing several of their respective applications.
- 23 February 2023
- Published by American Chemical Society (ACS) in Chemical Reviews
- Vol. 123 (6) , 3089-3126
Top Cited PapersOpen AccessA Brief Introduction to Chemical Reaction Optimization
From the start of a synthetic chemist's training, experiments are conducted based on recipes from textbooks and manuscripts that achieve clean reaction outcomes, allowing the scientist to develop practical skills and some chemical intuition. This procedure is often kept long into a researcher's career, as new recipes are developed based on similar reaction protocols, and intuition-guided deviations are conducted through learning from failed experiments. However, when attempting to understand chemical systems of interest, it has been shown that model-based, algorithm-based, and miniaturized high-throughput techniques outperform human chemical intuition and achieve reaction optimization in a much more time- and material-efficient manner; this is covered in detail in this paper. As many synthetic chemists are not exposed to these techniques in undergraduate teaching, this leads to a disproportionate number of scientists that wish to optimize their reactions but are unable to use these methodologies or are simply unaware of their existence. This review highlights the basics, and the cutting-edge, of modern chemical reaction optimization as well as its relation to process scale-up and can thereby serve as a reference for inspired scientists for each of these techniques, detailing several of their respective applications.
- Open Access
- 30 January 2023
- Published by American Chemical Society (ACS) in ChemRxiv
Accelerated Chemical Reaction Optimization using Multi-Task Learning
Functionalization of C–H bonds is a key challenge in medicinal chemistry, particularly for fragment-based drug discovery (FBDD) where such transformations need to be executed in the presence of polar functionality necessary for fragment-protein binding. New technologies such as high-throughput experimentation and self-optimization have the potential to revolutionize synthetic approaches to challenging target molecules in FBDD. Recent work has shown the effectiveness of Bayesian optimization (BO) for the self-optimization of chemical reactions, however, in all previous cases these algorithmic procedures have started with no prior information about the reaction of interest. In this work, we explore the use of multi-task Bayesian optimization (MTBO) in several in silico case studies by leveraging reaction data collected during related historical optimization campaigns to accelerate the optimization of new reactions - this was performed for Suzuki-Miyaura and C–N couplings. This methodology was then translated to real-world, medicinal chemistry applications in the yield optimization of several pharmaceutical intermediates using an autonomous flow-based reactor platform. The use of the MTBO algorithm was shown to be successful in determining optimal conditions (both continuous and categorical variables) of unseen experimental C–H activation reactions with differing substrates, demonstrating up to a 98 % cost reduction when compared to industry-standard process optimization techniques. Our findings highlight the effectiveness of the methodology as an enabling tool in medicinal chemistry workflows, where efficient utilization of precious starting materials is particularly important. This work represents a step-change in the utilization of previously obtained reaction data and machine learning with the ultimate goal of accelerated reaction optimization.
- 30 January 2023
- Published by American Chemical Society (ACS) in ChemRxiv
Open AccessAccelerated Chemical Reaction Optimization using Multi-Task Learning
Functionalization of C–H bonds is a key challenge in medicinal chemistry, particularly for fragment-based drug discovery (FBDD) where such transformations need to be executed in the presence of polar functionality necessary for fragment-protein binding. New technologies such as high-throughput experimentation and self-optimization have the potential to revolutionize synthetic approaches to challenging target molecules in FBDD. Recent work has shown the effectiveness of Bayesian optimization (BO) for the self-optimization of chemical reactions, however, in all previous cases these algorithmic procedures have started with no prior information about the reaction of interest. In this work, we explore the use of multi-task Bayesian optimization (MTBO) in several in silico case studies by leveraging reaction data collected during related historical optimization campaigns to accelerate the optimization of new reactions - this was performed for Suzuki-Miyaura and C–N couplings. This methodology was then translated to real-world, medicinal chemistry applications in the yield optimization of several pharmaceutical intermediates using an autonomous flow-based reactor platform. The use of the MTBO algorithm was shown to be successful in determining optimal conditions (both continuous and categorical variables) of unseen experimental C–H activation reactions with differing substrates, demonstrating up to a 98 % cost reduction when compared to industry-standard process optimization techniques. Our findings highlight the effectiveness of the methodology as an enabling tool in medicinal chemistry workflows, where efficient utilization of precious starting materials is particularly important. This work represents a step-change in the utilization of previously obtained reaction data and machine learning with the ultimate goal of accelerated reaction optimization.